Efficacy News and Research

RSS

In-hospital start of dapagliflozin shows no significant short-term benefit in heart failure patients

In-hospital initiation of dapagliflozin did not significantly reduce the short-term risk of cardiovascular death or worsening heart failure (HF) in patients admitted for HF, although positive effects were seen when combining trial data, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Aficamten outperforms beta-blockers in treating patients with obstructive hypertrophic cardiomyopathy

Aficamten treatment was associated with significant improvements in exercise capacity and symptoms compared with metoprolol in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in New England Journal of Medicine.

1 Sep 2025

Baxdrostat offers hope for millions with difficult-to-control high blood pressure

A new treatment has been shown to significantly lower blood pressure in people whose levels stay dangerously high, despite taking several existing medicines, according to the results of a Phase III clinical trial led by a UCL Professor.

1 Sep 2025

Drug-coated devices not associated with improved outcomes in patients with peripheral artery disease

Drug-coated stents and balloons were not associated with reduced risk of amputation or improved quality of life compared with uncoated devices in two trials in peripheral artery disease (PAD), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Shorter dual antiplatelet therapy may offer safety benefits in myocardial infarction patients

Three months of dual antiplatelet therapy (DAPT) was associated with signals suggesting improved survival and lower bleeding risk than 12 months of DAPT, in a real-world all-comer population of patients with myocardial infarction (MI), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Adding aspirin raises cardiovascular events in high-risk CCS patients on anticoagulants

Adding aspirin increased the risk of cardiovascular events, death and major bleeding in high-risk patients with chronic coronary syndrome (CCS) who had prior stenting and were receiving long-term chronic oral anticoagulation (OAC), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in New England Journal of Medicine.

1 Sep 2025

Triglyceride levels substantially reduced with olezarsen compared to placebo

Olezarsen decreased levels of triglycerides compared with placebo in patients with moderate hypertriglyceridemia and elevated cardiovascular risk, according to a late-breaking trial presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in New England Journal of Medicine.

1 Sep 2025

Baxdrostat demonstrates strong blood pressure control with favorable safety profile in phase III trial

Baxdrostat 1 mg or 2 mg once daily led to statistically significant reductions in blood pressure compared with placebo at 12 weeks in patients with uncontrolled or treatment-resistant hypertension, according to a late-breaking trial presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Vericiguat reduces mortality and hospitalizations in a broad range of patients with HFrEF

Vericiguat reduced the risk of cardiovascular mortality, heart failure (HF) hospitalizations and all-cause mortality across a broad range of patients with HF and reduced ejection fraction (HFrEF), according to a pooled analysis presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Extended apixaban therapy lowers recurrent VTE in patients with provoked events and enduring risk factors

Apixaban 2.5 mg twice daily significantly reduced symptomatic venous thromboembolism (VTE) recurrence, with a low risk of major bleeding, in patients with provoked VTE and enduring risk factors, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in New England Journal of Medicine.

1 Sep 2025

AMALFI trial finds small increase in AF diagnosis with mail-based ECG patch monitoring

A mail-based atrial fibrillation (AF) screening programme with ECG-patch monitoring led to a modest long-term increase in AF diagnosis and anticoagulation exposure in older patients at moderate-to-high stroke risk, according to a late-breaking trial presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in JAMA (The Journal of the American Medical Association).

1 Sep 2025

Lubiprostone shows promise in slowing kidney disease progression

Chronic kidney disease (CKD) is a major health issue worldwide. Many patients end up requiring regular dialysis to avoid kidney failure and stay alive.

1 Sep 2025

Constipation drug found to slow renal function decline in CKD patients

Chronic kidney disease (CKD) is a major health issue worldwide. Many patients end up requiring regular dialysis to avoid kidney failure and stay alive.

29 Aug 2025

How well does a cesarean risk calculator work?

Validated cesarean prediction tool effectively assesses delivery risks, supporting clinicians and patients in making informed decisions about labor induction.

29 Aug 2025

First clinical trial in cats tests targeted therapy for deadly head and neck cancer

Researchers have reported results from the first-ever clinical trial of a new class of targeted therapy in pet cats with head and neck squamous cell carcinoma (HNSCC)-a cancer which is notoriously deadly and difficult to treat.

28 Aug 2025

Older adults reveal what makes or breaks a shift to plant-based protein

Older Dutch adults identified health and taste as the key tipping points for shifting toward protein-rich plant-based diets. Knowledge, social context, and practical tools shaped adoption, while skepticism and habits limited change.

28 Aug 2025

Evidence-based calculator to guide hypertension treatment choices

A first-of-its-kind Blood Pressure Treatment Efficacy Calculator built on data from nearly 500 randomized clinical trials in over 100,000 people allows doctors to see by how much different medications are likely to lower blood pressure.

28 Aug 2025

Molecular profiling identifies prostate cancer patients who benefit most from chemotherapy

Testing the molecular profile of tumors identifies which patients with advanced prostate cancer are more likely to benefit from chemotherapy and live longer, sparing patients less likely to benefit from unpleasant side effects, according to a new study led by UCL researchers.

28 Aug 2025

New advances offer hope in the fight against KRAS-driven pancreatic cancer

Accounting for nearly 90% of all pancreatic cancers, pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of just 13%. Late-stage diagnosis, limited surgical options, and toxic chemotherapy regimens contribute to its poor outcomes.

28 Aug 2025

Illinois researchers highlight most effective nutritional approaches for GI distress in cancer care

Many modern cancer treatments are highly effective at reducing or eliminating tumors, but they can also cause severe gastrointestinal symptoms that impact patients' quality of life or lead to discontinuation of treatment.

28 Aug 2025

Previous
1
...
55
56
57
58
59
60
61
...
1332
Next

Efficacy News and Research

In-hospital start of dapagliflozin shows no significant short-term benefit in heart failure patients

Aficamten outperforms beta-blockers in treating patients with obstructive hypertrophic cardiomyopathy

Baxdrostat offers hope for millions with difficult-to-control high blood pressure

Drug-coated devices not associated with improved outcomes in patients with peripheral artery disease

Shorter dual antiplatelet therapy may offer safety benefits in myocardial infarction patients

Adding aspirin raises cardiovascular events in high-risk CCS patients on anticoagulants

Triglyceride levels substantially reduced with olezarsen compared to placebo

Baxdrostat demonstrates strong blood pressure control with favorable safety profile in phase III trial

Vericiguat reduces mortality and hospitalizations in a broad range of patients with HFrEF

Extended apixaban therapy lowers recurrent VTE in patients with provoked events and enduring risk factors

AMALFI trial finds small increase in AF diagnosis with mail-based ECG patch monitoring

Lubiprostone shows promise in slowing kidney disease progression

Constipation drug found to slow renal function decline in CKD patients

How well does a cesarean risk calculator work?

First clinical trial in cats tests targeted therapy for deadly head and neck cancer

Older adults reveal what makes or breaks a shift to plant-based protein

Evidence-based calculator to guide hypertension treatment choices

Molecular profiling identifies prostate cancer patients who benefit most from chemotherapy

New advances offer hope in the fight against KRAS-driven pancreatic cancer

Illinois researchers highlight most effective nutritional approaches for GI distress in cancer care

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News